A systematic review reported a significant improvement in the overall survival among trastuzumab-treated HER2-positive breast cancer patients in the modern era with the survival outcomes that are somewhat better compared to the other breast cancer subtypes [11]. This evidence concerns the gene ERBB2 and breast carcinoma.